Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Shares Issued (2016 - 2025)

Neurocrine Biosciences' Shares Issued history spans 16 years, with the latest figure at $37.3 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 273.0% year-over-year to $37.3 million; the TTM value through Dec 2025 reached $129.4 million, up 5.98%, while the annual FY2025 figure was $129.4 million, 5.98% up from the prior year.
  • Shares Issued reached $37.3 million in Q4 2025 per NBIX's latest filing, down from $45.6 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $69.9 million in Q1 2024 to a low of $1.8 million in Q4 2021.
  • Average Shares Issued over 5 years is $19.4 million, with a median of $14.8 million recorded in 2021.
  • Peak YoY movement for Shares Issued: crashed 81.01% in 2021, then surged 1266.67% in 2022.
  • A 5-year view of Shares Issued shows it stood at $1.8 million in 2021, then soared by 1266.67% to $24.6 million in 2022, then surged by 43.9% to $35.4 million in 2023, then crashed by 71.75% to $10.0 million in 2024, then surged by 273.0% to $37.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Shares Issued are $37.3 million (Q4 2025), $45.6 million (Q3 2025), and $14.4 million (Q2 2025).